Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDCRT and Pembrolizumab in Advanced Solid Tumors
NCT02987166Phase 1Completed
- Start
- Mar 2017
- Primary completion
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in solid tumor (3 arms). Primary endpoints: Adverse Event Profile at 27 months and Enumeration of T Cells in Tumor Tissue at Day 43. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02987166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987166.